Catalyst Pharmaceuticals v. Teva: Consent Judgment on Six Amifampridine Patents
Catalyst Pharmaceuticals and Serb SA sued Teva Pharmaceutical Industries and Teva Pharmaceuticals USA in the District of New Jersey, asserting six patents covering 3,4-diaminopyridine (amifampridine) formulations and degradation methods. The case resolved after 681 days with a consent judgment entered in favor of the plaintiffs on January 10, 2025.
Six-Patent ANDA Battle Over Amifampridine Ends in Plaintiffs’ Favor
Filed on March 1, 2023, in the District of New Jersey, this action was brought by Catalyst Pharmaceuticals, Inc. and Serb SA against Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. The plaintiffs asserted six U.S. patents — US11268128B2, US11274332B2, US11274331B2, US10626088B2, US10793893B2, and US11060128B2 — all directed to 3,4-diaminopyridine (amifampridine), including compositions, formulations, and methods relating to degradation of the active compound.
The case closed on January 10, 2025, when Judge Michael E. Farbiarz entered a consent judgment in favor of Catalyst Pharmaceuticals and Serb SA against Teva Pharmaceuticals USA, Inc. A consent judgment is a negotiated court order that carries the force of a judicial ruling without a contested trial, binding Teva to the agreed terms while the civil case was formally terminated. For Teva, this outcome typically signals an agreement to delay or restrict market entry in exchange for defined launch rights, though the precise commercial terms are not publicly disclosed.
At 681 days, the litigation ran longer than many ANDA-related consent judgments, suggesting the parties engaged in substantive negotiation over launch timing and licensing conditions before reaching agreement. The public record does not disclose whether Teva received an authorised generic arrangement or a specific entry date. The involvement of six patents — spanning both composition and degradation-related claims — indicates the plaintiffs built a layered enforcement strategy around amifampridine that would require Teva to address each independently.
Filing to Consent Judgment in 681 days
681 days — longer than the ANDA median, suggesting substantive negotiation before resolution
Consent judgment entered: what the resolution means for both parties
Consent judgment: a negotiated but binding court order
A consent judgment is entered when both parties agree to its terms and submit it to the court for approval. Once signed by the judge, it carries the same legal force as a litigated ruling. Here, Judge Farbiarz signed the order on January 10, 2025, formally terminating the civil case. Unlike a voluntary dismissal, a consent judgment is judicially enforceable and typically contains specific obligations binding on the defendant.
Consent JudgmentPlaintiffs secured an enforceable judgment without trial
For Catalyst Pharmaceuticals and Serb SA, a consent judgment entered in their favor is a commercially strong outcome: it protects the six asserted patents from an immediate validity challenge in this proceeding and constrains Teva’s ability to launch independently. The judgment likely includes defined conditions around any future Teva market entry, preserving the plaintiffs’ exclusivity position over amifampridine without the uncertainty of full litigation.
Plaintiffs prevailTeva bound by court order; market entry constrained
By consenting to judgment, Teva Pharmaceuticals USA, Inc. accepted binding court-ordered terms rather than contesting the six patents to judgment. This typically means Teva agreed to launch restrictions in exchange for a negotiated entry date or other commercial arrangement. The precise terms are not on the public docket. Teva retains the ability to seek IPR or other post-grant challenges, though consenting to judgment may complicate certain estoppel arguments.
Teva entry restrictedAmifampridine exclusivity reinforced across six patent claims
The resolution across six patents — covering compositions, formulations, and degradation methods — signals that Catalyst and Serb have built a defensible IP estate around amifampridine. Competitors assessing generic or biosimilar entry strategies should treat each of the six patents as independently enforced. The consent judgment outcome also suggests Catalyst has the litigation posture and resources to secure favorable terms without proceeding to trial.
Strong IP estate signalledFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Catalyst Pharmaceuticals, Inc. | Company | Specialty pharma company — holder of US11268128B2 and five further amifampridine patentsSearch in Eureka ↗ |
| Co-Plaintiff | Serb, SA | Company | Search in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Global generic pharmaceutical manufacturer and its U.S. operating subsidiarySearch in Eureka ↗ |
| Co-Defendant | Teva Pharmaceuticals USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Teva Pharmaceutical Industries Limited | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for Catalyst Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for Catalyst Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dennies Varughese | Attorney | Counsel for Catalyst Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Catalyst Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sterne Kessler Goldstein & Fox | Law Firm | Representing Catalyst Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Douglas Robert Weider | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant law firm | Greenberg Traurig LLP | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict text records a consent judgment entered in favor of Catalyst Pharmaceuticals and Serb SA against Teva Pharmaceuticals USA, Inc., with the civil case formally terminated. The phrasing ‘CONSENT JUDGMENT in favor of’ plaintiffs is legally significant: it is not a dismissal but a judicially endorsed resolution binding on Teva. The order was signed by Judge Farbiarz on January 10, 2025. Because no merits ruling was issued, the six asserted patents were not adjudicated for validity or infringement — they remain enforceable and unchallenged by this proceeding.
US11268128B2 — 3,4-diaminopyridine (amifampridine) degradation and compositions
The six asserted patents — US11268128B2, US11274332B2, US11274331B2, US10626088B2, US10793893B2, and US11060128B2 — collectively cover 3,4-diaminopyridine (amifampridine), the active ingredient in Firdapse, which is approved for treatment of Lambert-Eaton myasthenic syndrome (LEMS). The patents span a range of claims including pharmaceutical compositions, formulations, and methods directed to identifying or controlling degradation of the compound. The application priority dates range from the mid-2010s through 2021, suggesting Catalyst and Serb have prosecuted a continuing patent family to extend protection as the product matured commercially.
Amifampridine holds orphan drug designation and is subject to significant regulatory and IP exclusivity. The breadth of the six-patent portfolio — covering not just compositions but also degradation chemistry — makes it strategically difficult for generics to design around any single claim. For competitors in the rare neuromuscular disease drug space, this portfolio represents a high-cost challenge landscape: each patent would require independent IPR or ANDA Paragraph IV certification and litigation exposure. The consent judgment outcome reinforces that Catalyst is prepared to enforce each patent aggressively.
Should you run an FTO analysis against US11268128B2 and the Catalyst amifampridine portfolio?
Any company developing a generic, reformulated, or follow-on version of amifampridine (3,4-diaminopyridine) should treat all six patents as active enforcement risks. The consent judgment confirms that Catalyst and Serb are willing and able to litigate in the District of New Jersey and secure binding outcomes. R&D teams working on LEMS treatments, potassium channel blockers, or related neuromuscular compounds should map their product claims against each of the six patent families before committing to clinical or manufacturing investment.
PatSnap Eureka’s FTO Search Agent can run automated claim mapping across all six Catalyst amifampridine patents, identifying freedom-to-operate gaps, claim overlap risk, and prior art relevant to potential IPR petitions. Eureka’s AI-assisted landscape view also surfaces continuation applications that may not yet have issued, helping IP teams anticipate future enforcement risk before it materialises in an ANDA challenge letter.
Run a freedom-to-operate analysis on US11268128B2 to assess your product’s exposure
Run FTO in Eureka →Similar amifampridine and rare-disease ANDA patent cases in U.S. District Courts
Cases involving amifampridine or Paragraph IV ANDA challenges in the District of New Jersey, with comparable multi-patent enforcement strategies by branded rare-disease pharmaceutical companies.
What this case signals for the amifampridine and rare-disease pharma IP landscape
A six-patent consent judgment in favor of the innovator sends a clear enforcement signal to other potential generic entrants in the amifampridine market.
Multi-patent estates deter generic entry more effectively than single patents
By asserting six patents spanning compositions and degradation methods, Catalyst and Serb required Teva to clear every patent independently. This layered approach is consistent with an emerging enforcement strategy in rare-disease pharma: stacking method and formulation claims to raise the cost and complexity of generic challenges.
Consent judgments after long negotiations often signal commercially significant entry terms
A 681-day timeline before consent judgment suggests substantive back-and-forth over launch rights, royalties, or authorised generic arrangements. IP teams monitoring competitive entry windows in amifampridine should watch for any FDA Orange Book patent expiry disclosures or ANDA approval notices that may reveal the agreed launch date.
Catalyst v Teva — key questions answered
The consent judgment entered January 10, 2025 binds Teva Pharmaceuticals USA, Inc. to court-ordered terms agreed with Catalyst and Serb SA. While the specific launch conditions are not publicly disclosed, a consent judgment in the plaintiffs’ favor typically restricts the defendant’s ability to launch independently until agreed conditions — such as a specific date or license — are met.
Catalyst Pharmaceuticals and Serb SA asserted six patents: US11268128B2, US11274332B2, US11274331B2, US10626088B2, US10793893B2, and US11060128B2. All relate to 3,4-diaminopyridine (amifampridine), covering pharmaceutical compositions, formulations, and methods relating to degradation of the compound.
The case ran for 681 days, from March 1, 2023 to January 10, 2025. This duration is longer than many ANDA consent judgments, which typically resolve within 12 to 18 months. The extended timeline suggests the parties engaged in substantive negotiation over commercial entry terms — potentially including launch dates, authorised generic rights, or royalty arrangements — before agreeing to the final consent judgment.
The consent judgment does not adjudicate the validity of the six asserted patents on the merits. However, depending on the specific terms agreed, Teva may face contractual or estoppel constraints on filing IPR petitions. The public docket does not disclose whether the consent judgment includes any no-challenge clause. Absent such a clause, post-grant review at the USPTO remains a theoretical option, though consent to judgment may affect strategic timing.
Asserting patents covering both pharmaceutical compositions and degradation methods creates a layered enforcement barrier. A generic entrant cannot avoid infringement simply by reformulating the compound if degradation-related process or analytical method claims also apply. This multi-claim-type strategy — evident across the six Catalyst patents — is consistent with best-practice IP portfolio building in orphan and rare-disease drug development, where market exclusivity is commercially critical.
PatSnap Eureka searches patents and litigation data to answer instantly.